It is now clear that the ␤ 2 -adrenergic receptor continuously oscillates between various conformations in the basal state, and that agonists act to stabilize one or more conformations. It is conceivable that synthetic agonists might be engineered to preferentially confine the receptor to certain conformations deemed clinically important while having a less stabilizing effect on unwanted conformations. In addition, studies of genetically engineered mice have revealed previously unrecognized cross-talk between the ␤ 2 -receptor and phospholipase C, such that removal of the primary dilating pathway results in downregulation of constrictive pathways and overactivity of the dilating pathway increases the contractile response. These results indicate a dynamic interaction between ␤ 2 -receptor activity and G q -coupled receptors that constrict the airway. Potentially, then, during chronic ␤-agonist therapy, expression of phospholipase C is increased, the functions of G q -coupled constrictive receptors are enhanced, and there may be an increased tendency for clinical decompensation due to asthma and chronic obstructive pulmonary disease triggers. Antagonists to these receptors might be able to act synergistically with chronic ␤-agonists to block the effect of phospholipase C. Alternatively, perhaps novel phospholipase C antagonists would provide the most efficacious approach to blocking the physiologic sequelae of cross-talk between the ␤ 2 -receptor and phospholipase C.
nents in various cell types and genetically altered mice, concepts about ␤ 2 AR signaling have changed fundamentally.
STRUCTURE OF THE ␤ 2 AR
Like all GPCRs, the ␤ 2 AR has seven transmembrane-spanning segments, which are ␣ helices. As a consequence, there are three extracellular and three intracellular loops. The amino terminus is extracellular and the carboxy terminus is intracellular. Several posttranslational modifications are noteworthy. The human ␤ 2 AR is N-glycosylated at amino acids 6, 15, and 187; these are important for proper insertion of the receptor into the membrane as well as for agonist trafficking (1, 2) . Notably, the glycosylation site at amino acid 187 is restricted to higher order primates (1) . At amino acid position 341, the cysteine of the human ␤ 2 AR is palmitoylated (3) . This acts to anchor this part of the carboxy terminus to the cell membrane and imparts several functional features (3) . The region between the seventh transmembranespanning domain and the palmitoylated cysteine has also been shown to be an ␣ helix in the homologous protein rhodopsin. Therefore, this region is sometimes denoted as the fourth intracellular loop or the eighth ␣ helix. Agonist-promoted phosphorylation of the ␤ 2 AR occurs via protein kinase A at serines in the third intracellular loop and the proximal cytoplasmic tail. Such phosphorylation decreases the coupling of the receptor to the G protein G s and is one mechanism of agonist-promoted desensitization (4) . A family of kinases termed G protein-coupled receptor kinases (GRKs) phosphorylates the ␤ 2 AR at multiple serines and threonines in the cytoplasmic tail (4) . Subsequent binding of ␤-arrestins to the phosphorylated receptor serves to (1 ) uncouple the receptor from G s and thus desensitize receptor function (4), (2 ) promote receptor internalization, and (3 ) by virtue of the scaffolding action of ␤-arrestins, bring other proteins into the receptor's microdomain (5) . An example of the latter is phosphodiesterase-4, which is recruited by ␤-arrestin and acts to metabolize the locally generated cAMP (6) . Another posttranslational modification of the ␤ 2 AR is ubiquitination, which occurs via an E3 ligase and is a prerequisite for receptor degradation (7).
AGONIST INTERACTION WITH THE ␤ 2 AR: WHAT IS THE "ACTIVE" STATE?
The traditional concept of agonist activation of the ␤ 2 AR was akin to a lock and key: the agonist fit into the receptor and caused it to adopt a conformation that was favorable for coupling to G s . However, it is now clear that the receptor is continuously "toggling" between various conformations in the absence of agonist. This is readily appreciated by measuring basal adenylyl cyclase activity in membranes from transfected cells expressing various levels of the ␤ 2 AR (8) ( Figure 1A ). As expression increases, so does basal (nonagonist) adenylyl cyclase activity. In this model, agonist occupancy increases the probability that the receptor will be in the active state ( Figure 1B) . Neutral antagonists do not affect the equilibrium and thus adenylyl cyclase activities are not altered. (Of course, in a clinical setting in which the levels of synthetic or endogenous agonist are elevated, neutral antagonists nevertheless have a physiologic effect, because they block agonist access to the receptor.) Inverse agonists actually lower basal adenylyl cyclase activities because they preferentially bind to receptor in the inactive state. Data have suggested that most antagonists probably have the properties of an inverse agonist, but their efficacy in decreasing adenylyl cyclase is low and is probably clinically insignificant. Partial agonists either stabilize a different conformation of the receptor compared with full agonists or stabilize the same active conformation as a full agonist but do so less frequently.
Oscillation of the ␤ 2 AR between various conformations brings into question whether there is a single "active" conformation. Traditionally, the active state was defined by a single function, which was coupling to G s , with the "readout" being cAMP production or adenylyl cyclase activities. However, it is now clear that multiple signals are promoted by ␤ 2 AR, and that the "ideal" conformation for one effector signal may not be the same as that for another. For example (9) , the ␤ 2 AR activates the sodiumhydrogen exchanger regulatory factor by direct interaction with the carboxy-terminal domain of the receptor (no G protein is required). Conceivably, an agonist might preferentially activate the G s pathway compared with the sodium-hydrogen exchanger regulatory factor pathway. Other conformations, such as those that favor GRK-mediated phosphorylation, ␤-arrestin binding, mitogen-activated protein kinase activation, or G i coupling, might also be selectively activated, or not activated, by synthetic agonists. Indeed, for the closely related ␣ 2 ARs, it has been shown that there is a poor correlation between agonist-promoted phosphorylation of ␣ 2 AR by GRKs and the intrinsic activity (compared with the prototypic full agonist epinephrine) of the given synthetic agonist (10) ( Figure 1C) . Similarly, some agonists show a relative preference for ␣ 2 AR-G s coupling over ␣ 2 AR-G i coupling (11) . Taken together, the data suggest that GPCRs, including the ␤ 2 AR, oscillate between many conformations in the basal state, and that agonists act to stabilize one or more conformations. Thus, it is conceivable that synthetic agonists might be engineered to preferentially confine the receptor to certain conformations deemed clinically important (e.g., coupling to G s ) while having a less stabilizing effect on potentially unwanted conformations such as phosphorylation by GRKs.
AFTER RECEPTOR ACTIVATION: DEEP PATHWAY EFFECTS
With prolonged agonist activation, ␤ 2 ARs undergo processes that limit function, generically termed desensitization. These events are critical for the cell to integrate the myriad signals being received, and for adaptation to physiologic and pathologic states. Desensitization may also limit the therapeutic effectiveness of prolonged agonist exposure (tachyphylaxis), although this may be highly dependent on the structure of the agonist, the cell type, the disease being treated, and the outcome measures deemed to be relevant. Long-term desensitization of the ␤ 2 AR is the result of the net effect of several processes, including the short-term events of protein kinase A and GRK phosphorylation, G i coupling, and the long-term events leading to a decrease in receptor expression (termed downregulation), which is due to transcriptional as well as protein degradation mechanisms.
Several studies (12, 13) have begun to investigate the effects of long-term ␤ 2 AR activation on signaling elements far removed from the receptor, G protein, and effector. The bases for such investigations with ␤ 2 AR in asthma and chronic obstructive pulmonary disease (COPD) were intriguing clinical observations made during chronic ␤-agonist therapy that were not readily reconciled by the traditional desensitization paradigm. For example, some, but certainly not all, studies have shown that ␤-agonists administered on a regular schedule result in a decrease in bronchodilator function. ␤ 2 AR desensitization presumably causes this decrease in bronchodilator function. In addition, chronic use of ␤-agonists causes an increase in sensitivity (i.e., a decrease in the provocative concentration of an agonist causing a 20% fall in FEV 1 ) to the bronchoconstrictive effects of agents such as methacholine and histamine. This phenomenon appears to be observed more consistently than tachyphylaxis of bronchodilatation from chronic ␤-agonists. It has also been ascribed to ␤ 2 AR desensitization, supposedly because of less opposed bronchoconstriction, and thus increased hyperreactivity.
We hypothesized that these events might be explained by regulation of other signaling elements apart from the receptor (12) . To explore this possibility, we studied genetically altered mice in which the ␤ 2 AR was overexpressed in airway smooth muscle (mimicking constant ␤ 2 AR activation) and mice in which the ␤ 1 -and ␤ 2 AR genes were ablated (equivalent to an absolute lack of airway ␤AR activity). In the ␤AR knockout (␤AR Ϫ/Ϫ ) mice we were surprised to find that removal of this bronchodilating pathway resulted in a paradoxical decrease in the bronchoconstricting effect of methacholine and the thromboxane mimetic U46619, as studied by whole-animal plethysmography (Figure 2A ). This finding was confirmed by measuring airway resistance in an intubated mouse model, in which the contractile responses to methacholine and serotonin were also found to be decreased ( Figure 2B ). Finally, tracheal rings were studied ex vivo, and the phenomenon was again observed ( Figure 2C ). Here we were able to expose the rings to ␤-escin, an agent that makes the cell permeable, allowing an influx of extracellular calcium and subsequent contraction via non-GPCR mechanisms. We found that contraction was the same for ␤AR Ϫ/Ϫ rings compared with rings from wild-type mice, which indicated that the basic contractile apparatus was intact in ␤AR Ϫ/Ϫ mice. To isolate the mechanism of regulation of these constrictive G q -coupled receptors by the absence of ␤AR, we generated primary airway smooth muscle cells from each line. As shown in Figure 3 , inositol 1,4,5-trisphosphate (IP 3 ) production was decreased in ␤AR Ϫ/Ϫ mice. In addition, consistent with what we term antithetic regulation, IP 3 production was increased in ␤ 2 ARoverexpressing (␤ 2 AR-OE) mice. This, along with the ␤-escin data, indicated that the mechanism of this regulation was likely to be at the level of a receptor, G q , or the effector phospholipase C (PLC), rather than IP 3 precursors, the endoplasmic reticulum IP 3 receptor, or altered intracellular Ca 2ϩ stores. We believed it unlikely that the G q -coupled receptors that we activated (M 3 -muscarinic, 5HT 2 , and thromboxane) were all downregulated in ␤AR Ϫ/Ϫ mice and upregulated in ␤AR-OE mice. We thus concentrated on elements shared by these receptors. Immunoblotting of airway smooth muscle cell lysates revealed no change in G ␣q content or in the levels of the cognate G protein for the ␤ 2 AR, G ␣s . However, in ␤AR Ϫ/Ϫ mice, the PLC-␤ 1 content of ␤AR Ϫ/Ϫ airway smooth muscle cells was markedly decreased compared with cells from wild-type mice (Figure 3 ). And, in ␤ 2 AR-OE cells, PLC-␤ 1 was increased about threefold over wild type. The decrease in PLC-␤ 1 in ␤AR Ϫ/Ϫ mice was entirely consistent with the decreases in bronchoconstriction and IP 3 production observed in response to G q -coupled receptor agonists. Tracheal ring studies from ␤ 2 AR-OE mice revealed what might be predicted from the IP 3 results and the immunoblotting: acetylcholine evoked greater contraction and had greater potency in these mice compared with wild type ( Figure 2D ). These data revealed a previously unrecognized interaction between ␤ 2 AR and PLC. It appears that there is a mechanism in place to cross-regulate bronchodilating and bronchoconstricting responses. Removal of the primary dilating pathway resulted in a downregulation of constrictive pathways, and overactivity of the dilating pathway had the effect of increasing the contractile response. Data from Callaerts-Vegh have shown in a mouse model of asthma that chronic treatment (28 days) with ␤-blockers decreases contractile responses (13) , analogous to the results we found in ␤AR Ϫ/Ϫ mice (12). These results indicate a dynamic interaction between ␤ 2 AR activity and receptors that act to constrict the airway. The local concentrations of agonists for these receptors, such as acetylcholine, serotonin, thromboxane, histamine, certain prostaglandins, and certain leukotrienes (acting at the cysteinyl leukotriene-1 receptor) are increased in asthma, and potentially in chronic bronchitis. Thus, during chronic ␤-agonist therapy, when PLC expression is increased and the functions of these G q -coupled constrictive receptors are enhanced, there may be an increased tendency for clinical decompensation due to infection, allergy, or other asthma/COPD triggers. As such, antagonists to these receptors may be particularly useful under these circumstances. Interestingly, as monotherapy in asthma, these antagonists (such as ipratropium, montelukast, and seratrodast) have limited efficacy. However, they could act synergistically with chronic ␤-agonists to block the PLC effect and thus achieve a more satisfactory clinical response. Still, because there are so many G q -coupled constrictive receptors, it will be difficult to fully block this pathway with receptor antagonists. Perhaps new pharmacologic agents that antagonize PLC-␤ 1 would provide the most efficacious approach to blocking the physiologic sequelae of the chronic ␤-agonist cross-talk. The events discussed above are also expected in patients with COPD who are treated long term with ␤-agonists. However, we know less about which endogenous G q -coupled receptors are activated in this disease. Certainly the favorable response to ipratropium in COPD and the synergy of this anticholinergic with ␤-agonists are consistent with the cholinergic pathway as an active participant. The potential clinical relevance of ␤ 2 AR-PLC cross-talk is illustrated in Figure 4 .
It is intriguing to consider this paradigm in the light of several studies that show associations between ␤ 2 AR polymorphisms (14, 15) and worsening asthma control (16) (17) (18) . Because the trigger for this PLC-based constrictive pathway cross-talk is the ␤ 2 AR, any genetic variation that alters expression, function, or regulation of the ␤ 2 AR will alter the degree of augmentation of G q receptor signaling. As such, a ␤ 2 AR polymorphism might also influence the response to a G q receptor antagonist such as ipratropium. This indeed appears to be the case in the betaadrenergic response by genotype (BARGE) trial (18) . Patients with asthma who were homozygous for Arg-16, when withdrawn from ␤-agonist therapy and provided with ipratropium for rescue purposes, had a significant increase in morning peak expiratory flow. Gly-16 homozygotes showed no such improvement under the same conditions. Although the trial was not specifically designed to address ipratropium responsiveness, the results are nevertheless consistent with the concept of chronic ␤ 2 AR crosstalk with M 3 -muscarinic receptor signaling of the airway.
